...
机译:The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment
Univ Hosp Vall dHebron, Paediat Nephrol Dept, Barcelona, Spain;
Univ Colorado, Sch Med, Dept Pediat, Renal Sect, Aurora, CO USA;
Pusan Natl Univ, Childrens Hosp, Dept Pediat, Yangsan, South KoreaCent Michigan Univ, Fac Pediat Sci, Mt Pleasant, MI 48859 USAUniv Nebraska Med Ctr, Omaha Childrens Hosp & Med Ctr, Med Ctr, Div Pediat Nephrol, Omaha, NE USAAlexion Pharmaceut Inc, Clin & Nonclin Pharmacol, Boston, MA USAAlexion Pharmaceut Inc, Biostat, Boston, MA USAAlexion Pharmaceut Inc, Clin Dev, Boston, MA USASeoul Natl Univ, Coll Med, Dept Pediat, Div Pediat Nephrol, Seoul, South KoreaEmory Univ, Sch Med, Div Pediat Nephrol, Atlanta, GA USA;
atypical hemolytic uremic syndrome; complement; eculizumab; hemolytic uremic syndrome; ravulizumab; thrombotic microangiopathy;